Augmentation therapy with serial intravenous ketamine over 18 months in a patient with treatment resistant depression

Clinical Neuropharmacology

Volumn 38, Issue 5, 2015, Pages 212-216

  Hassamal, Sameer ^a,b   Spivey, Margaret ^a   Pandurangi, Ananda K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Department of Addiction Psychiatry UCLA Kern   (United States)

Author keywords

Antidepressant augmentation; Case report; IV ketamine; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; DEXAMPHETAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; KETAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; PAROXETINE; PROTRIPTYLINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

AGED; ANHEDONIA; ARTHRITIS; ARTICLE; BECK DEPRESSION INVENTORY; BEDTIME DOSAGE; BRAIN DEPTH STIMULATION; CASE REPORT; COGNITIVE DEFECT; DISEASE COURSE; DISEASE RE-EMERGENCE; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MEDICAL HISTORY; MENTAL PATIENT; MIGRAINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; SLEEP DISORDERED BREATHING; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; TIME FACTOR;

DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS;

EID: 84941884143     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000104     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention (CDC). Current depression among adults-United States, 2006 and 2008. MMWR Morb Mortal Wkly Rep 2010;59(38):1229-1235.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-3105.
3. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10(11):e1001547.
4. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011;475(7354):27-30.
5. ∗D report. Am J Psychiatry 2006;163(11):1905-1917.
6. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010;167(11):1305-1320.
7. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52(1):46-54.
8. Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Am J Psychiatry 2012;169(12):1238-1244.
9. Messer M, Haller IV, Larson P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 2010;22(4):442-444.
10. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994;9(Suppl 2):5-10.
11. Lapidus KA, Soleimani L, Murrough JW. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat 2013;9:1101-1112.
12. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003;140(1-2):1-47.
13. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(11 Suppl 8):S14-S23.
14. O'Connor RM, Finger BC, Flor PJ, et al. Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol 2010;639(1-3):123-131.
15. Naughton M, Clarke G, O'Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 2014;156:24-35.
16. Aan Het Rot M, Zarate CA Jr, Charney DS, et al. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72(7):537-547.
17. Müller MJ, Himmerich H, Kienzle B, et al. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 2003;77(3):255-260.
18. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74(4):250-256.
19. Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 2009;24(3):133-138.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
21. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-864.
22. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170(10):1134-1142.
23. Diaz Granados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71(12):1605-1611.
24. Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67(2):139-145.
25. Mathew SJ, Murrough JW, Aan Het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010;13(1):71-82.
26. Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2013;147(1-3):416-420.
27. Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014;155:123-129.
28. Cusin C, Hilton GQ, Nierenberg AA, et al. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012;169(8):868-869.
29. Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014;215(2):355-361.
30. Okamoto N, Nakai T, Sakamoto K, et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 2010;26(3):223-227.
31. Johansen-Berg H, Gutman DA, Behrens TE, et al. Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex 2008;18(6):1374-1383.
32. Malone DA Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009;65(4):267-275.
33. Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008;64(6):461-467.
34. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 1992;39(3):61-68.
35. Tsai GE. Searching for rational anti N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007;64(9):1099-1100 author reply 1100-1091.
36. Szymkowicz SM, Finnegan N, Dale RM. Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol 2014;34(2):285-286.